{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:23:15Z","timestamp":1793996595833,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41401-025-01739-9","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T14:05:56Z","timestamp":1770300356000},"page":"1629-1642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Asiatic acid promotes CD8+ T cell-mediated antitumor immunity by targeting HDAC8\/CXCL10 axis in hepatocellular carcinoma"],"prefix":"10.1038","volume":"47","author":[{"given":"Yu-chuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-lian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-yuan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-xian","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-kai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-hong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"1739_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-cancer J Clin. 2024;74:229\u201363.","journal-title":"Ca-cancer J Clin"},{"key":"1739_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1355812","volume":"15","author":"RC Chick","year":"2024","unstructured":"Chick RC, Ruff SM, Pawlik TM. Neoadjuvant systemic therapy for hepatocellular carcinoma. Front Immunol. 2024;15:1355812.","journal-title":"Front Immunol"},{"key":"1739_CR3","doi-asserted-by":"crossref","unstructured":"Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. 2021;22:5801.","DOI":"10.3390\/ijms22115801"},{"key":"1739_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.655697","volume":"12","author":"J Giraud","year":"2021","unstructured":"Giraud J, Chalopin D, Blanc JF, Saleh M. Hepatocellular carcinoma immune landscape and the potential of immunotherapies. Front Immunol. 2021;12:655697.","journal-title":"Front Immunol"},{"key":"1739_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023;78:770\u201382.","journal-title":"J Hepatol"},{"key":"1739_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02477-6","volume":"24","author":"Y Liu","year":"2025","unstructured":"Liu Y, Wang Y, Wang S, Li J, He W, Fan X, et al. Turning cold tumors into hot tumors to ignite immunotherap. Mol Cancer. 2025;24:254.","journal-title":"Mol Cancer"},{"key":"1739_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinom. Nat Rev Clin Oncol. 2022;19:151\u201372.","journal-title":"Nat Rev Clin Oncol"},{"key":"1739_CR8","doi-asserted-by":"crossref","unstructured":"Palomero J, Panisello C, Lozano-Rabella M, Tirtakasuma R, D\u00edaz-G\u00f3mez J, Grases D, et al. Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer. J Immunother Cancer. 2022;10:e005443.","DOI":"10.1136\/jitc-2022-005443"},{"key":"1739_CR9","doi-asserted-by":"crossref","unstructured":"Huang H, Huang Z, Ge J, Yang J, Chen J, Xu B, et al. CD226 identifies functional CD8+ T cells in the tumor microenvironment and predicts a better outcome for human gastric cancer. Front Immunol. 2023;14:1150803.","DOI":"10.3389\/fimmu.2023.1150803"},{"key":"1739_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1638-6","volume":"10","author":"J Lv","year":"2019","unstructured":"Lv J, Jia Y, Li J, Kuai W, Li Y, Guo F, et al. Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment. Cell Death Dis. 2019;10:415.","journal-title":"Cell Death Dis"},{"key":"1739_CR11","doi-asserted-by":"crossref","unstructured":"Xu H, Van der Jeught K, Zhou Z, Zhang L, Yu T, Sun Y, et al. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. J Clin Invest. 2021;131:e146832.","DOI":"10.1172\/JCI146832"},{"key":"1739_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15853","volume":"9","author":"L Ding","year":"2023","unstructured":"Ding L, Liu T, Ma J. Neuroprotective mechanisms of asiatic acid. Heliyon. 2023;9:e15853.","journal-title":"Heliyon"},{"key":"1739_CR13","doi-asserted-by":"crossref","unstructured":"Varada S, Chamberlin SR, Bui L, Brandes MS, Gladen-Kolarsky N, Harris CJ, et al. Oral asiatic acid improves cognitive function and modulates antioxidant and mitochondrial pathways in female 5xFAD mice. Nutrients. 2025;17:729.","DOI":"10.3390\/nu17040729"},{"key":"1739_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3389\/fimmu.2017.00785","volume":"8","author":"H Lv","year":"2017","unstructured":"Lv H, Qi Z, Wang S, Feng H, Deng X, Ci X. Asiatic acid exhibits anti-inflammatory and antioxidant activities against lipopolysaccharide and d-galactosamine-induced fulminant hepatic failure. Front Immunol. 2017;8:785.","journal-title":"Front Immunol"},{"key":"1739_CR15","volume":"12","author":"J Li","year":"2021","unstructured":"Li J, Chen K, Huang J, Chu D, Tian M, Huang K, et al. Asiatic acid induces endoplasmic reticulum stress and activates the Grp78\/IRE1\u03b1\/JNK and calpain pathways to inhibit tongue cancer growth. Front Phaemacol. 2021;12:690612.","journal-title":"Front Phaemacol"},{"key":"1739_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34047","volume":"10","author":"X Lin","year":"2024","unstructured":"Lin X, Fang Y, Mi X, Fu J, Chen S, Wu M, et al. Asiatic acid inhibits cervical cancer cell proliferation and migration via PI3K\/AKT\/mTOR signaling pathway. HELIYON. 2024;10:e34047.","journal-title":"HELIYON"},{"key":"1739_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3389\/fimmu.2020.00976","volume":"11","author":"N Karin","year":"2020","unstructured":"Karin N. CXCR3 ligands in cancer and autoimmunity, chemoattraction of effector T cells, and beyon. Front Immunol. 2020;11:976.","journal-title":"Front Immunol"},{"key":"1739_CR18","first-page":"24","volume":"109","author":"N Karin","year":"2018","unstructured":"Karin N, Razon H. Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokone. 2018;109:24\u20138.","journal-title":"Cytokone"},{"key":"1739_CR19","doi-asserted-by":"crossref","unstructured":"Reschke R, Enk AH, Hassel JC. Chemokines and cytokines in immunotherapy of melanoma and other tumors: from biomarkers to therapeutic targets. Int J Mol Sci. 2024;25:6532.","DOI":"10.3390\/ijms25126532"},{"key":"1739_CR20","doi-asserted-by":"crossref","unstructured":"Kim JY, Cho H, Yoo J, Kim GW, Jeon YH, Lee SW, et al. Pathological role of HDAC8: cancer and beyond. Cells. 2022;11:3161.","DOI":"10.3390\/cells11193161"},{"key":"1739_CR21","doi-asserted-by":"crossref","unstructured":"Yang W, Feng Y, Zhou J, Cheung OK, Cao J, Wang J, et al. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Sci Transl Med. 2021;13:eaaz6804.","DOI":"10.1126\/scitranslmed.aaz6804"},{"key":"1739_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111756","volume":"184","author":"B Wolff","year":"2019","unstructured":"Wolff B, J\u00e4nsch N, Sugiarto WO, Fr\u00fchschulz S, Lang M, Altintas R, et al. Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors. Eur J Med Chem. 2019;184:111756.","journal-title":"Eur J Med Chem"},{"key":"1739_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1021\/ct9005322","volume":"6","author":"R Wu","year":"2009","unstructured":"Wu R, Hu P, Wang S, Cao Z, Zhang Y. Flexibility of catalytic zinc coordination in thermolysin and HDAC8: a born-oppenheimer ab initio QM\/MM molecular dynamics study. J Chem Theor Comput. 2009;6:337.","journal-title":"J Chem Theor Comput"},{"key":"1739_CR24","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.4049\/jimmunol.1400420","volume":"193","author":"SD Ha","year":"2014","unstructured":"Ha SD, Han CY, Reid C, Kim SO. HDAC8-mediated epigenetic reprogramming plays a key role in resistance to anthrax lethal toxin-induced pyroptosis in macrophages. J Immunol. 2014;193:1333\u201343.","journal-title":"J Immunol"},{"key":"1739_CR25","doi-asserted-by":"publisher","first-page":"16313","DOI":"10.1021\/acs.jmedchem.2c01132","volume":"65","author":"P Sun","year":"2022","unstructured":"Sun P, Wang J, Khan KS, Yang W, Ng BW, Ilment N, et al. Development of alkylated hydrazides as highly potent and selective class I histone deacetylase inhibitors with T cell modulatory properties. J Med Chem. 2022;65:16313\u201337.","journal-title":"J Med Chem"},{"key":"1739_CR26","doi-asserted-by":"crossref","unstructured":"Yuliana A, Jheng HF, Kawarasaki S, Nomura W, Takahashi H, Ara T, et al. \u03b2-adrenergic receptor stimulation revealed a novel regulatory pathway via suppressing histone deacetylase 3 to induce uncoupling protein 1 expression in mice beige adipocyte. Int J Mol Sci. 2018;19:2436.","DOI":"10.3390\/ijms19082436"},{"key":"1739_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1166128","volume":"14","author":"J Zhang","year":"2023","unstructured":"Zhang J, Lei F, Tan H. The development of CD8 T-cell exhaustion heterogeneity and the therapeutic potentials in cancer. Front Immunol. 2023;14:1166128.","journal-title":"Front Immunol"},{"key":"1739_CR28","doi-asserted-by":"crossref","unstructured":"Roussot N, Ghiringhelli F, R\u00e9b\u00e9 C. Tumor immunogenic cell death as a mediator of intratumor CD8 T-cell recruitment. Cells. 2022;11:3672.","DOI":"10.3390\/cells11223672"},{"key":"1739_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Tar. 2020;5:146.","journal-title":"Signal Transduct Tar"},{"key":"1739_CR30","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1053\/j.gastro.2018.09.051","volume":"156","author":"TF Greten","year":"2019","unstructured":"Greten TF, Lai CW, Li G, Staveley-O\u2019Carroll KF. Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology. 2019;156:510\u201324.","journal-title":"Gastroenterology"},{"key":"1739_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.107032","volume":"199","author":"R Wang","year":"2024","unstructured":"Wang R, Wang C, Lu L, Yuan F, He F. Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: a comprehensive review with future perspectives. Pharmacol Res. 2024;199:107032.","journal-title":"Pharmacol Res"},{"key":"1739_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109604","volume":"121","author":"SM Tang","year":"2020","unstructured":"Tang SM, Deng XT, Zhou J, Li QP, Ge XX, Miao L. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomed Pharmacother. 2020;121:109604.","journal-title":"Biomed Pharmacother"},{"key":"1739_CR33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2174\/1871520619666191211103006","volume":"20","author":"MT Islam","year":"2020","unstructured":"Islam MT, Ali ES, Uddin SJ, Khan IN, Shill MC, de Castro ESJ, et al. Anti-cancer effects of asiatic acid, a triterpene from Centilla asiatica L: a review. Anti-cancer Agent Med Chem. 2020;20:536\u201347.","journal-title":"Anti-cancer Agent Med Chem"},{"key":"1739_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104683","volume":"153","author":"K Deepak","year":"2020","unstructured":"Deepak K, Vempati R, Nagaraju GP, Dasari VR, Nagini S, Rao DN, et al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020;153:104683.","journal-title":"Pharmacol Res"},{"key":"1739_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherap. Cancer Cell. 2021;39:845\u201365.","journal-title":"Cancer Cell"},{"key":"1739_CR36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.22.01015","volume":"41","author":"VM Patil","year":"2023","unstructured":"Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, et al. Low-dose immunotherapy in head and neck cancer: a randomized study. J Clin Oncol. 2023;41:222\u201332.","journal-title":"J Clin Oncol"},{"key":"1739_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera FG, Ronet C, Ochoa De Olza M, Barras D, Crespo I, Andreatta M, et al. Low-Dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 2022;12:108\u201333.","journal-title":"Cancer Discov"},{"key":"1739_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8458","volume":"6","author":"ME Mikucki","year":"2015","unstructured":"Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6:7458.","journal-title":"Nat Commun"},{"key":"1739_CR39","doi-asserted-by":"crossref","unstructured":"Reschke R, Yu J, Flood B, Higgs EF, Hatogai K, Gajewski TF. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J Immunothe Cancer. 2021;9:e003521.","DOI":"10.1136\/jitc-2021-003521"},{"key":"1739_CR40","doi-asserted-by":"crossref","unstructured":"Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6:a026831.","DOI":"10.1101\/cshperspect.a026831"},{"key":"1739_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01770-4","volume":"39","author":"T Singh","year":"2022","unstructured":"Singh T, Kaur P, Singh P, Singh S, Munshi A. Differential molecular mechanistic behavior of HDACs in cancer progression. Med Oncol. 2022;39:171.","journal-title":"Med Oncol"},{"key":"1739_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","volume":"17","author":"MQ Shi","year":"2024","unstructured":"Shi MQ, Xu Y, Fu X, Pan DS, Lu XP, Xiao Y, et al. Advances in targeting histone deacetylase for treatment of solid tumors. J Hematol Oncol. 2024;17:37.","journal-title":"J Hematol Oncol"},{"key":"1739_CR43","doi-asserted-by":"publisher","first-page":"4956","DOI":"10.1038\/s41388-020-1337-x","volume":"39","author":"P An","year":"2020","unstructured":"An P, Chen F, Li Z, Ling Y, Peng Y, Zhang H, et al. HDAC8 promotes the dissemination of breast cancer cells via AKT\/GSK-3\u03b2\/Snail signal. Oncogene. 2020;39:4956\u201369.","journal-title":"Oncogene"},{"key":"1739_CR44","doi-asserted-by":"crossref","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002\u201314.","DOI":"10.1016\/S0140-6736(21)01206-X"},{"key":"1739_CR45","doi-asserted-by":"publisher","first-page":"11612","DOI":"10.1016\/j.ejmech.2024.116129","volume":"265","author":"B Cheng","year":"2024","unstructured":"Cheng B, Pan W, Xiao Y, Ding Z, Zhou Y, Fei X, et al. HDAC-targeting epigenetic modulators for cancer immunotherapy. Eur J Med Chem. 2024;265:11612.","journal-title":"Eur J Med Chem"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01739-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01739-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01739-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T08:10:47Z","timestamp":1779437447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01739-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1739"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01739-9","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}